Red cell distribution width is associated with cardiovascular risk and disease parameters in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 54, Issue 4, 2014, Pages 641-646

  Rodríguez Carrio, Javier ^a   Alperi López, Mercedes ^b   López, Patricia ^a   Alonso Castro, Sara ^b   Ballina García, Francisco J ^b   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Biomarker; Cardiovascular disease; Red cell distribution width; Rheumatoid arthritis

Indexed keywords

ACUTE PHASE PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; ERYTHROCYTE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; RED CELL DISTRIBUTION WIDTH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

EID: 84926512009     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu345     Document Type: Article

References (20)

1. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
2. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:125-32.
3. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
4. Lopez-Mejias R, Genre F, Garcia-Bermudez M et al. The 11q23.3 genomic region-rs964184-is associated with cardiovascular disease in patients with rheumatoid arthritis. Tissue Antigens 2013;82:344-7.
5. Korpela M, Laasonen L, Hannonen P et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum 2004;50:2072-81.
6. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:70-5.
7. Ajeganova S, Andersson ML, Frostegard J, Hafstrom I. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 2013;40:1958-66.
8. Uyarel H, Isik T, Ayhan E, Ergelen M. Red cell distrubition width (RDW): a novel risk factor for cardiovascular disease. Int J Cardiol 2012;154:351-2.
9. Ani C, Ovbiagele B. Elevated red blood cell distribution width predicts mortality in persons with known stroke. J Neurol Sci 2009;277:103-8.
10. Perlstein TS, Weuve J, Pfeffer MA, Beckman JA. Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med 2009;169:588-94.
11. Lippi G, Targher G, Montagnana M et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med 2009;133:628-32.
12. Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R et al. TNFA-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011; 216:125-30.
13. Lappe JM, Horne BD, Shah SH et al. Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clin Chim Acta 2011;412:2094-9.
14. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
15. van Nies JA, Krabben A, Schoones JW et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2013;73:861-70.
16. Raza K, Falciani F, Curnow SJ et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7:R784-95.
17. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56:2905-12.
18. Georgiadis AN, Voulgari PV, Argyropoulou MI et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008;38:13-9.
19. van Nies JA, de Jong Z, van der Helm-van Mil AH et al. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology 2010;49: 2210-6.
20. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.